Evidence map›Paper›PMID 32328047›Full record

ReviewFrontiers in microbiology2020

A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan.

Kazuo Itabashi, Tokuo Miyazawa, Akihiko Sekizawa, Akifumi Tokita, Shigeru Saito, Hiroyuki Moriuchi, Yasuhito Nerome, Kaoru Uchimaru, Toshiki Watanabe

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. How Can We Prevent Mother-to-Child Transmission of HTLV-1?International journal of molecular sciences · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Kazuo ItabashiShowa University Hospital, Tokyo, Japan.
Tokuo MiyazawaDepartment of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
Akihiko SekizawaJapan Association of Obstetricians and Gynecologists, Tokyo, Japan.
Akifumi TokitaJapanese Pediatric Association, Tokyo, Japan.
Shigeru SaitoThe University of Toyama, Toyama, Japan.
Hiroyuki MoriuchiDepartment of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yasuhito NeromeFaculty of Medicine, School of Health Sciences, Kagoshima University, Kagoshima, Japan.
Kaoru UchimaruGraduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Toshiki WatanabeFuture Center Initiative, and Research Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPJapan Pediatric Society · JPKagoshima University · JPNagasaki University · JPShowa University · JPShowa University Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the first 30 weeks of gestation, during regular pregnancy checkups. Pregnant women tested positive on the antibody screening test undergo a confirmatory test, either western blotting or line immunoassay. In indeterminate case, polymerase chain reaction (PCR) is used as a final test to diagnose infection. Pregnant women tested positive on a confirmatory or PCR test are identified as HTLV-1 carriers. As breastfeeding is a predominant route of postnatal HTLV-1 mother-to-child transmission, exclusive formula feeding is widely used as a postnatal preventive measure. Although there is insufficient evidence that short-term breastfeeding during ≤3 months does not increase the risk of mother-to-child transmission compared to exclusive formula feeding, this feeding method is considered if the mother is eager to breastfeed her child. However, it is important that mothers and family members fully understand that there is an increase in the risk of mother-to-child transmission when breastfeeding would be prolonged. As there are only a few clinical studies on the protective effect of frozen-thawed breastmilk feeding on mother-to-child transmission of HTLV-1, there is little evidence to recommend this feeding method. Further study on the protective effects of these feeding methods are needed. It is assumed that the risk of anxiety or depression may increase in the mothers who selected exclusive formula feeding or short-term breastfeeding. Thus, an adequate support and counseling for these mothers should be provided. In addition to raising public awareness of HTLV-1 infection, epidemiological data from the nationwide program needs to be collected and analyzed. In most cases, infected children are asymptomatic, and it is necessary to clarify how these children should be followed medically.

Indexed as

confirmatory testhuman T-cell leukemia virus type-1infectionmother-to-child transmissionnationwide antenatal screeningprevention

Identifiers

PMID32328047
PMCPMC7160230
OpenAlexW3016089675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.